In addition, participants in the exercise group were found to have 21% lower odds of rapid eGFR decline (defined as a decline of 6.7% per year), suggesting this exercise program may help preserve kidney function
Moini, J., & Piran, P
This analysis corroborated the ML models suggesting a small, albeit significant, contribution of microbiota variations on circulating TMAO and identified a bacterium newly associated with higher serum TMAO in BMIS
Why it Works: Multi-dimensional formula addresses the facial changes that occur when using GLP-1 agonists Formula works in 4D to improve the appearance of facial skin deflation, loose, sagging, crepey skin texture, dehydration, and deep wrinkles Proprietary XOSM technology boosts formula performance Improves the appearance of skin firmness, density and skin texture quality Deeply nourishes and hydrates, plumping the skin Protects and nourishes the skins barrier Clinicals: 20.1% increase in facial volume 22.5% increase in firmness 23.2% increase in net elasticity 20.7% decrease in wrinkles 21.8% increase in hydration Disclaimer: Based on a 12-week clinical study of 29 participants ages 3565, who have experienced weight loss due to the use of one of the following: GLP-1 agonists, GIP, other weight loss promoting drugs or gastric bypass surgery, with twice daily application of VOL.U.LIFT
